Norway wealth fund divests from Paz
The fund has sold its $7 million stake in Paz because "The company owns and operates infrastructure supplying fuel to Israeli settlements in the occupied West Bank."
Navitas founders set for huge returns
With the Shenandoah gas reservoir about to come on tap, Gideon Tadmor and his partners expect annual royalties in the hundreds of millions of shekels.
Is Nice ready to bounce back?
A year after Barak Eilam stepped down as CEO, Nice is 50% below its peak, but Oppenheimer's Sergey Vastchenok says fears about the company are misplaced.
Teva on course for 2027 targets
The Israeli pharmaceutical company's 3,000 layoffs will help the company achieve its targets for growth and higher profitability.
Harel, George Horesh bid for Cal
The bid for Discount Bank's 72% stake in credit card company Cal is non-binding at this stage. Several foreign investment firms have also expressed interest.
Teva receives FDA approval for biosimilar
The FDA has ruled that SELARSDI, which Teva has launched with Alvotech, is interchangeable with Stelara for treating adult and pediatric psoriatic arthritis and plaque psoriasis, as well as Crohn's disease, and ulcerative colitis.
Shekel weakens amid security escalation
Mizrahi Tefahot Bank: The shekel is weakening due to increasing security tensions, expanding activity in Gaza, statements by the Houthis and Iran, and to some extent a correction.